Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$63.37−1.32 (-2.04%)
Close on Nov 13, 2026Market cap $9.43BP/E –Yield 0.00%
Vaxcyte operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vaxcyte's operating cash flow for the twelve months ending Sep 30, 2026 was -$962.01M. For fiscal 2025 it was -$655.58M. The highest annual figure on record is -$30.47M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$655.58M | – |
| FY2024 | Dec 31, 2024 | -$452.63M | – |
| FY2023 | Dec 31, 2023 | -$296.79M | – |
| FY2022 | Dec 31, 2022 | -$170.60M | – |
| FY2021 | Dec 31, 2021 | -$121.39M | – |
| FY2020 | Dec 31, 2020 | -$46.63M | – |
| FY2019 | Dec 31, 2019 | -$47.15M | – |
| FY2018 | Dec 31, 2018 | -$30.47M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$224.08M | – |
| Q2 FY2026 | Jun 30, 2026 | -$232.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$280.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$224.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$143.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$121.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$166.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$111.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$60.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$121.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$159.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$128.81M | – |
| Q3 FY2023 | Sep 30, 2023 | -$57.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$62.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.69M | – |
| Q4 FY2022 | Dec 31, 2022 | -$65.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$38.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$39.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.70M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.68M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.77M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.63M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.41M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.46M | – |
See a number that looks wrong?